POSTER SESSION IV Tuesday, March 1, 2005   —  1:00 - 4:30 PM Convention Center Exhibit Hall B GYNECOLOGIC PATHOLOGY 115 Interobserver Variation in the Assessment of Extra-Ovarian Implants of Serous Borderline Tumors (Serous Tumors of Low Malignant Potential) (856) CB Gilks, JK McKenney, S Kalloger, TA Longacre - University of British Columbia, Vancouver, BC, Canada; University of Arkansas for Medical Sciences, Little Rock, AR; Stanford University, Stanford, CA 116 Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors (864) C-L Ho, RJ Kurman, T-L Wang, I-M Shih - Johns Hopkins Medical Institutions, Baltimore, MD 117 The Roles of Mitogen-Activated Protein Kinase in Serous Borderline Tumor and Low-Grade Serous Carcinoma (863) C-L Ho, G Pohl, RJ Kurman, T-L Wang, I-M Shih - Johns Hopkins Medical Institutions, Baltimore, MD; National Chung-Kung University, Tainan, Taiwan 118 Cytoplasmic CD24 Expression in Advanced Ovarian Serous Borderline Tumors (834) YL Choi, SY Kang, EY Cho, GH Ahn - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 119 Does the Lack of THY1 Gene Expression Support Different Histogenetic Mechanisms for Ovarian Serous Borderline and Invasive Tumors? (895) F Liu, CJ Sung, C Zhang, MR Quddus, JM Kasznica, MM Steinhoff, WD Lawrence - Women & Infants Hospital; Brown Medical School, Providence, RI 120 Increased Expression of the p110 alpha Catalytic Subunit of PI3K and Genomic Gain of PIK3CA Have Different Impact on Clinical Prognosis, and Are Associated with Different Morphological Subgroups of Ovarian Serous Neoplasia (953) A Staebler, O Buchweitz, B Karberg, J Behm, H Schmidt - University of Muenster, Muenster, Germany 121 Immunohistochemical Studies of Clear Cell Carcinomas of the Ovary and Non-Small Cell Carcinomas of the Lung with Clear Cell Features (865) NR Howell, W Zheng, L Cheng, PB Kane, SX Liang - SUNY, Stony Brook, NY; Yale Sch of Med, New Haven, CT; Indiana Univ Sch of Med, Indianapolis, IN 122 Platelet Derived Growth Factor Receptor-alpha Expression Is Frequently Observed in Clear Cell Carcinoma of fhe Ovary (845) RE Emerson, LA Baldrige, D Matei - Indiana University School of Medicine, Indianapolis, IN 123 DcR3 Expression in the Development and Behavior of Epithelial Ovarian Tumors (815) AJ Ali, BVS Kallakury, RA Ambros, CE Sheehan, S Kim, S Yang, JS Ross, L Zhang - Albany Medical College, Albany, NY; Georgetown University Hospital, Washington, DC; Lombardi Cancer Center, Washington, DC 124 Cell Signaling Pathways in Ovarian Epithelial Tumors: 4EBP1 as a Novel Prognostic Factor (32) Castellvi, A Garcia, J de la Torre, F Rojo, A Gil, S Ramon y Cajal - Vall d'Hebron University Hospital, Barcelona, Spain 125 Ephrin B1 in Ovarian Tumours: A Potential Therapeutical Target Expressed in a Subset of Carcinomas (855) A Garcia, J Castellvi, J De la Torre, J Hernandez, F Rojo, S Ramon y Cajal - Vall d'Hebron University Hospital, Barcelona, Spain 126 Differential Expression of Cadherins and Catenins Associates with Distinct Ovarian Carcinoma Types (859) D Hardisson, D Sarrió, G Hernandez-Cortés, C Sánchez-Estévez, G Moreno-Bueno, A Suárez, J Palacios - Hospital La Paz (UAM), Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain 127 COX-2, EGFR, WT-1 and HER-2/neu Expression in Epithelial Ovarian Tumors (909) JM Mosquera, K Meehan, J Rotmensch, EL Yordan, F Manosca, AM Gown, P Bitterman - Rush University Medical Center, Chicago, IL; PhenoPath Laboratories, Seattle, WA 128 c-erbB2 Status in Ovarian Carcinomas: A Combined Evaluation Using FISH, CISH and Immunohistochemistry (883) E Kostopoulou, D Kaisaridou, M Ioannou, M Nakou, M Netsika, G Kalodimos, F Karassavidou, S Barbanis, G Koukoulis - University of Thessaly, Larissa, Greece 129 Expression of ERK1/2 and EGFR and Their Relationship with Survival: A Study of 90 Cases of Ovarian Epithelial Tumors (957) G Toledo, JI Echeveste, M Collantes, A Martinez-Penuela, A Panizo, J Pardo - Clinica Universitaria. Universidad de Navarra, Pamplona, Navarra, Spain 130 C-Met Expression in Different Types of Ovarian Epithelial Tumors (960) M Turkyilmaz, M Tretiakova, T Krausz, E Lengyel, A Montag - University of Chicago Hospitals, Chicago, IL 131 Survivin Expression in Epithelial Ovarian Neoplasia (901) J Malysz, SW Lee, TM Nazir, CE Sheehan, JS Ross, RA Ambros - Albany Medical College, Albany, NY; Medical College, Hallym University, Chunchon, South Korea, Korea 132 Prognostic Significance of Tumor Infiltrating Lymphocytes (TILs) in Ovarian Cancer and Their Relationship to Cancer-Testis (CT) Antigen Expression (943) E Sato, S Olson, AA Jungbluth, O Kunle, LJ Old - Memorial Sloan-Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY 133 Clinical Significance of pSTAT3 Expression in Ovarian Carcinoma (935) DG Rosen, HM Amin, RC Bast, R Lai, J Liu - The University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada 134 Expression of hTERT and hTR RNA Correlates with Poor Prognosis in Ovarian Carcinoma (936) DG Rosen, G Yang, JA Lanza, AT Tong, J Liu - MD Anderson Cancer Center, Houston, TX 135 The Clinical Role of Phospholipase A2 in Metastatic Ovarian Carcinoma (857) M Gurevitz, CG Trope, B Davidson, R Reich - School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; The Norwegian Radium Hospital, University of Oslo, Oslo, Norway; The Norwegian Radium Hospital, University of Oslo, Oslo, Norway 136 CDX2 Immunohistochemical Staining Patterns in Mucinous Neoplasms of the Female Genital Tract (922) KJ Park, M Bramlage, EC Pirog, LH Ellenson - Memorial Sloan Kettering Cancer Center, New York, NY; New York Presbyterian Hospital Cornell Medical Center, New York, NY 137 Ovarian Atypical Proliferative (Borderline) Mucinous Tumors: Gastrointestinal and Seromucinous (Endocervical) Types Are Immunophenotypically Distinctive (961) R Vang, AM Gown, TS Barry, D Wheeler, B Ronnett - Johns Hopkins Hospital, Baltimore, MD; PhenoPath Laboratories, Seattle, WA; Quest Diagnostics, Inc., Las Vegas, NV 138 Mucinous Carcinomas of the Ovary: Immunohistochemistry Can Help Distinguish Primary Mucinous Ovarian Carcinoma from Metastatic Mucinous Carcinoma of Appendiceal Origin (861) MS Hirsch, JL Hornick - Brigham & Women's Hospital; Harvard Medical School, Boston, MA 139 CDX2 Versus CK20 and CK7 for Distinction of Primary Ovarian Mucinous Tumors from Metastatic Mucinous Carcinomas Involving the Ovary (962) R Vang, AM Gown, TS Barry, D Wheeler, B Ronnett - Johns Hopkins Hospital, Baltimore, MD; PhenoPath Laboratories, Seattle, WA; Quest Diagnostics, Inc., Las Vegas, NV 140 Estrogen (ER) and Progesterone Receptor (PR) Expression in Ovarian Mucinous Tumors: Utility for Distinction of Primary Tumors from Metastases (963) R Vang, AM Gown, TS Barry, D Wheeler, B Ronnett - Johns Hopkins Hospital, Baltimore, MD; PhenoPath Laboratories, Seattle, WA; Quest Diagnostics, Inc., Las Vegas, NV 141 Diagnostic Utility of Immunohistochemical Expression of Cdx2 and Cytokeratin (CK)7/20 in Metastatic Carcinomas of the Ovary from Gastrointestinal Tract (858) HI Ha, H-I Lee, MJ Kim, JY Ro, K-R Kim - University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea 142 Immunohistochemistry for CDX-2, Cytokeratin 7 and 20, CEA, CA125, and Her-2/neu in Distinction of Metastatic Carcinoma in the Ovary from Primary Ovarian Carcinoma: A Tissue Microarray Study (875) MJ Kim, YK Bae, JH Choi - Yeungnam University College of Medicine, Daegu, Korea 143 Utility of MUC2 and Thymidylate Synthase Immunohistochemistry in Ovarian Mucinous Tumors Associated with "Pseudomyxoma Peritonei" (894) F Liu, CJ Sung, C Zhang, C Browar, MR Quddus, MM Steinhoff, WD Lawrence - Women & Infants Hospital, Brown Medical School, Providence, RI 144 KOC Expression in Ovarian Mucinous Tumors: Potential Role in Differentiating Mucinous Tumors of Low Malignant Potential from Mucinous Carcinomas (835) A Ciampa, C Li, G Fanger, K Dresser, A Khan, K Rock, B Xu - UMass Medical School, Worcester, MA; Corixa Corporation, Seattle, WA 145 Women with Undiagnosed Colorectal Adenocarcinomas Presenting with Ovarian Metastases: Clinicopathologic Features and Comparison to Women with Known Colorectal Adenocarcinoma Having Ovarian Metastases (872) K Judson, R Vang, B Ronnett - The Johns Hopkins Hospital, Baltimore, MD 146 Lung Carcinoma Metastatic to the Ovary - A Clinicopathologic Study of 33 Cases (869) JA Irving, RH Young - Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA 147 Gastrointestinal Stromal Tumors Metastatic to the Ovary (887) MF Lerwill, JA Irving, RH Young - Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA 148 HBME1, Galectin3, and CITED1: Markers of Malignancy in Struma Ovarii (944) J Schmidt, R Rucker-Schmidt, C Quigley, W Welch, K Lee, C Crum, V Nosé - Brigham & Women's Hospital, Harvard Medical School, Boston, MA 149 WT-1, TTF-1 and HPV Testing Can Distinguish between Small Cell Carcinomas of the Ovary, Cervix and Lung (831) JW Carlson, MR Nucci, J Brodsky, CP Crum, MS Hirsch - Brigham & Women's Hospital, Boston, MA 150 Expression of Wilms Tumor Gene (WT-1) in Primary Peritoneal Serous Carcinomas (833) M Chivukula, M Kapali - Magee-Womens Hospital,University of Pittsburgh, Pittsburgh, PA 151 Early Complete Hydatidiform Mole: A Clinicopathologic Study of 210 Cases (852) M Fukunaga - Jikei University Daisan Hospital, Komae, Tokyo, Japan 152 Interobserver and Intraobserver Variablity in the Diagnosis of Hydatidiform Mole (853) M Fukunaga, H Katabuchi, T Nagasaka, Y Mikami, S Minamiguchi, JM Lage - Jikei University, Komae, Tokyo, Japan; Kumamoto University, Kumamoto, Japan; Nagoya University, Nagoya, Aichi, Japan; Tohoku University, Sendai, Miyagi, Japan; National Kyoto Medical Center, Kyoto, Japan; Medical University of South Carolina, Charleston, SC